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Background-—Brain lipoprotein metabolism is dependent on lipoprotein particles that resemble plasma high-density lipoproteins
but that contain apolipoprotein (apo) E rather than apoA-I as their primary protein component. Astrocytes and microglia secrete
apoE but not apoA-I; however, apoA-I is detectable in both cerebrospinal ﬂuid and brain tissue lysates. The route by which plasma
apoA-I enters the central nervous system is unknown.
Methods and Results-—Steady-state levels of murine apoA-I in cerebrospinal ﬂuid and interstitial ﬂuid are 0.664 and 0.120 lg/
mL, respectively, whereas brain tissue apoA-I is 10% to 15% of its levels in liver. Recombinant, ﬂuorescently tagged human apoA-I
injected intravenously into mice localizes to the choroid plexus within 30 minutes and accumulates in a saturable, dose-dependent
manner in the brain. Recombinant, ﬂuorescently tagged human apoA-I accumulates in the brain for 2 hours, after which it is
eliminated with a half-life of 10.3 hours. In vitro, human apoA-I is speciﬁcally bound, internalized, and transported across conﬂuent
monolayers of primary human choroid plexus epithelial cells and brain microvascular endothelial cells.
Conclusions-—Following intravenous injection, recombinant human apoA-I rapidly localizes predominantly to the choroid plexus.
Because apoA-I mRNA is undetectable in murine brain, our results suggest that plasma apoA-I, which is secreted from the liver and
intestine, gains access to the central nervous system primarily by crossing the blood–cerebrospinal ﬂuid barrier via speciﬁc cellular
mediated transport, although transport across the blood–brain barrier may also contribute to a lesser extent. ( J Am Heart Assoc.
2014;3:e001156 doi: 10.1161/JAHA.114.001156)
Key Words: ApoA-I • central nervous system • cerebrovascular endothelium • choroid plexus • transport
P lasma high-density lipoprotein (HDL) is an extremelyheterogeneous class of lipoproteins that comprises >200
individual lipid species and >80 different proteins in normo-
lipidemic plasma.1,2 HDL is best known for its pivotal role in
reverse cholesterol transport, in which cholesterol is removed
from peripheral tissues and transported back to the liver for
excretion into the bile. HDL and its principal protein
component, apolipoprotein (apo) A-I, also possess several
potent vasoprotective properties, including stimulating endo-
thelial repair, inhibiting inﬂammation, suppressing endothelial
cell apoptosis and platelet aggregation, and preventing lipid
oxidation.3
Despite composing only 2.5% of body mass, the highly
vascularized brain consumes 20% of the body’s cardiac
output, 20% of oxygen consumption, and 25% of glucose
consumption.4 Cerebrovascular dysfunction is increasingly
recognized as contributing to the pathogenesis of several
neurological disorders, including Alzheimer disease (AD). Most
AD patients have biochemical, morphological, and functional
changes to the cerebrovasculature, including accumulation of
amyloid in cerebral blood vessels, which is known as cerebral
amyloid angiopathy, in addition to the parenchymal amyloid
plaques and neuroﬁbrillary tangles that deﬁne AD.4,5 Further-
more, several comorbidities that increase AD risk, including
hypertension, stroke, hypercholesterolemia, cardiovascular
disease, and type 2 diabetes mellitus, all converge on vascular
dysfunction.6,7 Intriguingly, HDL function is also impaired in
many of these comorbidities.8,9
ApoA-I has previously been implicated in cerebrovascular
and central nervous system (CNS) function5; deleting apoA-I
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from the APP/PS1 mouse model of AD exacerbates cognitive
deﬁcits and selectively increases cerebral amyloid angiopa-
thy.10 In contrast, transgenic mice that overexpress human
apoA-I 2-fold from its endogenous promoter exhibit improved
cognitive performance, decreased cerebral amyloid angiopathy,
and reduced CNS inﬂammation.11 In vitro, apoA-I can bind b-
amyloid (Ab) and reduce Ab-induced cytotoxicity.10,12 In
ABCA1/ mice, CNS apoE levels are reduced by 80%,13
whereas apoA-I levels are reduced up to 50% in brain tissue
despite an 85% decrease in plasma apoA-I.14 Intriguingly, apoA-I
levels are dramatically increased in both brain and cerebrospi-
nal ﬂuid (CSF) in brain-speciﬁc ABCA1/ mice, whereas CNS
apoE levels are reduced.15 In contrast, brain-selective overex-
pression of ABCA1 in PDAPP mice does not alter CNS apoE or
apoA-I levels.16 Finally, treatment of APP/PS1 mice with
GW3965, a liver X receptor agonist that stimulates systemic
ABCA1 expression, increases apoA-I levels by 250% in brain
tissue and 300% in CSF without signiﬁcantly altering plasma or
liver apoA-I levels.14 Together, these observations suggest that
the CNS may have mechanisms to alter apoA-I levels in
response to ﬂuctuating plasma concentrations.
This study was performed speciﬁcally to characterize the
route by which circulating apoA-I gains access to the CNS,
ﬁlling a substantial gap in our understanding of apoA-I
metabolism in the brain. Although in vitro cultures of porcine
brain capillary endothelial cells have been reported to express
and secrete apoA-I,17 it is not clear whether this occurs in
other species. In this study, we used lipid-free human apoA-I
(hapoA-I), both recombinant and serum derived, to investigate
the transport of peripheral apoA-I into the CNS. Following
intravenous injection in C57Bl/6 mice, the vast majority of
hapoA-I in the CNS is present within the choroid plexus and is
undetectable in the brain microvasculature. In vitro, however,
hapoA-I can be speciﬁcally bound, internalized, and trans-
ported across conﬂuent monolayers of primary human
choroid plexus epithelial cells as well as primary human brain
microvascular endothelial cells. Our results suggest that, in
vivo, the preferred route of entry of hapoA-I into the brain is
likely across the blood–CSF barrier (BCSFB), although we
cannot rule out some contribution of hapoA-I transport across
the blood–brain barrier (BBB).
Materials and Methods
Animals
Three- to ﬁve-month-old female C57Bl/6 and apoA-I/ mice
(Jackson Laboratory, Bar Harbor, ME, USA) were maintained
on a chow diet (PMI LabDiet 5010; LabDiet). All animal
procedures were approved by the Canadian Council of Animal
Care and the University of British Columbia Committee on
Animal Care (A10-0231, A09 0916).
Recombinant HapoA-I Production and Labeling
Recombinant hapoA-I (rhapoA-I) was expressed in Escherichia
coli from plasmids encoding full-length hapoA-I containing an
N-terminal histidine tag and 1 of 5 C-terminal cysteine
substitution mutations (S231C, K239C, L240C, T242C, or
Q243C). Protein was puriﬁed with a His-trap chelating column
(GE Healthcare), equimolar amounts of each mutant were
pooled, and endotoxin was removed using an EndoTrap red
endotoxin removal column (Hyglos). Final endotoxin levels
were <10 endotoxin units/mg., as measured by the Limulus
Amebocyte Lysate Kinetic-QCL Assay (Lonza Bioscience).
RhapoA-I was labeled using Alexa Fluor 647 C2 malemide
(Alexa647–rhapoA-I), following the manufacturer’s instruc-
tions (A-20347; Invitrogen) at a molar ratio of 1:1.
Puriﬁcation of Serum-Derived HapoA-I and
Labeling
Puriﬁed lipid-poor hapoA-I derived from healthy human serum
was generously provided by CSL Behring. For in vitro
experiments, hapoA-I was labeled with Alexa Fluor 488
carboxylic acid tetraﬂuorophenyl ester, according to the
manufacturer’s instructions (A-10235; Invitrogen).
Intravenous Injection and CSF, Plasma, and
Tissue Collection
Alexa647–rhapoA-I or saline as vehicle was injected into the
tail vein of C57Bl/6 mice at concentrations ranging from 7.5
to 120 mg/kg. Tissues were collected 30 minutes to
24 hours after injection. Mice were anesthetized with
20 mg/kg xylazine (Bayer) and 150 mg/kg ketamine (Bime-
da-MTC) intraperitoneally. CSF was isolated as described,14
and only samples that contained <20 red blood cells per cubic
millimeter were used for subsequent analyses. EDTA blood
was collected via cardiac puncture, centrifuged at 21 000g for
10 minutes at 20°C and stored at 80°C. Animals were
perfused for 7 minutes at 8 mL/min with phosphate-buffered
saline containing 2500 U/L heparin. Tissues (liver, kidney,
and brain) were removed, weighed, and frozen at 80°C. Half
of the brain was ﬁxed in 10% neutral buffered formalin
followed by cryoprotection in 30% sucrose prior to cryostat
sectioning for histological analysis.
Interstitial Fluid Collection
In vivo microdialysis was performed in 3- to 4-month-old
C57Bl/6 mice, as described previously.18 All microdialysis
procedures were performed in accordance with guidelines
established by the animal studies committee at Washington
University. Mice were anesthetized using 1.5% to 2.5%
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isoﬂurane then mounted onto a manipulator arm–equipped
small animal stereotaxic apparatus (David Kopf Instruments).
A bore hole (1 mm diameter) was then created above the
left hippocampus (bregma 3.1 mm, 2.5 mm lateral; dura
mater 1.2 mm). A second bore hole (0.75 mm) was placed in
the right anterior quadrant of the skull for placement of an
anchoring bone screw. An AtmosLM guide cannula (PEG-X;
Eicom) was then stereotactically inserted and cemented into
the left hippocampal formation (12° angle, dura mater
1.2 mm). The wound was closed using surgical adhesive,
and the animal was placed into a clean cage and provided
with access to food and water ad libitum. Next, 1000-kDa
microdialysis probes (AtmosLM microdialysis probe, PEP-X-
0Y; Eicom) were ﬂushed with artiﬁcial CSF.19 Mice were then
brieﬂy anesthetized with isoﬂurane, and probes were inserted
into the hippocampus through the guide cannula. Mice were
then placed into a Raturn stand-alone caging system (BASi).
The ﬂow rate was a constant 1.1 lL/min inlet and 1.0 lL/
min outlet using a MAB20 dual-channel peristaltic pump
(SciPro). The microdialysis probe equilibrated in brain for
12 hours before sample collection started. Samples were
collected every 2 hours for 12 hours using a refrigerated
fraction collector (Univentor 820 Microsampler; SciPro). At
the end of each experiment, samples were aliquoted and then
immediately frozen at 80°C and stored for future analysis.
Intravenous Injection of Evans Blue
A 2% solution of Evans blue dye (Sigma-Aldrich) in saline was
injected at 4 mL/kg into the tail vein 30 minutes prior to
sacriﬁce in mice injected with 7.5 or 120 mg/kg saline or
Alexa647– rhapoA-I 1.5 hours earlier. Pictures of liver, kidney,
brain, and plasma were taken to illustrate the distribution and
uptake of Evans blue, which binds to plasma albumin.
Because Evans blue is also ﬂuorescent, images of intact half
brains were acquired using the Maestro ﬂuorescent imager
with the same conditions as those detailed below.
mRNA Extraction and Quantitative Reverse
Transcriptase Polymerase Chain Reaction
RNA was extracted from tissues and cells using TRIzol
(Invitrogen) and treated with DNase I prior to cDNA synthesis.
The cDNA was generated using oligo(dT) primers and TaqMan
reverse transcription reagents (Applied Biosystems). Primers
were designed using Primer Express software (Applied
Biosystems). Sequences are murine apoA-I forward (50
GACCTGCGCCATAGTCTGATG 30) and reverse (50 TCAGAGTCT
CGCTGGCCTTG 30), murine b-actin forward (50 ACGGCCAGGT-
CATCACTATTG 30) and reverse (50 CAAGAAGGAAGGCTGGAAA
AG 30), human apoA-I forward (50 ACCACGCCAAGGCCACCGAG
30) and reverse (50 CTCGAGCGCTCAGGAAGCT 30), and human
GAPDH forward (50CCTGCACCACCAACTGCTTA 30) and reverse
(50CATGAGTCCTTCCACGATACCA 30). Quantitative reverse
transcriptase polymerase chain reaction was done with SYBR
Green reagents (Applied Biosystems) on a StepOnePlus system
(Applied Biosystems). Cycling conditions were 50°C for 2 min-
utes, 95°C for 10 minutes, then 40 cycles at 95°C for
15 seconds and 60°C for 1 minute, followed by dissociation
at 95°C for 15 seconds, 60°C for 20 seconds, and 95°C for
15 seconds. Each sample was assayed at least in duplicate,
normalized to b-actin or GAPDH, and analyzed with Applied
Biosystems 7000 system SDS software v1.2, using the relative
standard curve method.
Protein Extraction
For murine apoA-I, tissues were homogenized in 8 volumes of
ice-cold RIPA buffer, sonicated at 20% output for 10 seconds,
and then centrifuged at 8600g for 10 minutes at 4°C. For
hapoA-I ELISAs, tissues were homogenized in 2 volumes of
ice-cold PBS containing a cOmplete protease inhibitor cocktail
tablet (Roche Diagnostics), and sonicated at 20% output for
10 seconds. Protein concentrations were determined using
the BCA Protein Assay (Pierce).
Immunoblot
Equal volumes of CSF (5 lL), plasma (1 to 5 lL), interstitial
ﬂuid (ISF; 20 lL), and tissue lysate (150 to 200 lg) were
subjected to immunoblotting, as described.14 The following
antibodies were used: rabbit anti-mouse apoA-I (1:500-
1:2000, K23001R; Meridian), mouse anti-albumin (0.2 to
0.5 mg/mL, A90-134; Bethyl Laboratories), and mouse
anti-GAPDH (0.2 mg/mL, MAB374; Millipore), followed by
horseradish peroxidase–conjugated secondary antibodies.
Each sample was analyzed at least in duplicate on
independent gels.
ELISA Measurement of ApoA-I
Endogenous murine apoA-I levels in plasma, CSF, and ISF
were measured by commercial ELISA (MBS2019017; MyBio-
Source) following the manufacturer’s instructions. RhapoA-I
levels were quantiﬁed by ELISA (A70101; ALerCHEK). Back-
ground absorption from saline-injected controls were sub-
tracted prior to calculation of rhapoA-I concentration. For
tissue, rhapoA-I concentration was normalized to total
protein.
Imaging and Histology
Image cubes of intact ﬁxed half brains were collected using an
excitation ﬁlter of 575 to 605 nm, an emission ﬁlter of
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645 nm, and acquisition settings of 630 to 850 nm collected
in 10-nm steps (Maestro imaging system; PerkinElmer).
Images were unmixed using real component analysis and
quantiﬁed using threshold segmentation.
For immunohistochemical analysis, 3 to 4 sagittal sections
of 25 to 40 lm and spaced 500 lm apart were analyzed per
animal. Floating sections were blocked for 1 hour with 5%
normal goat serum in PBS, stained with Cy3 anti-mouse IgG
(1:100, 715-165-150; Jackson Laboratory) for 36 to 48 hours
at 4°C, washed with PBS, and stained overnight with
ﬂuorescein-conjugated tomato lectin (0.2 mg/mL, FL1171;
Vector Laboratories) to visualize endothelial and epithelial
cells. Sections were washed with PBS and mounted on
Superfrost Plus glass slides (Fisher Scientiﬁc) using Vecta-
shield Hard Set mounting medium (Vector Laboratories).
Images were taken using a BX61 ﬂuorescent microscope
(Olympus) and quantiﬁed using Image-Pro software (Media
Cybernetics) with the following ﬁlters: Alexa Fluor 488 for
ﬂuorescein, TexRed for Cy3, and Cy5 for Alexa Fluor 647. The
automated OxPlow program within InVivo software (Media
Cybernetics) was used to visualize the entirety of the sagittal
section. A rectangular border encompassing the section was
deﬁned in OxPlow, and the microscope was instructed to take
sequential images following a “snake-like” pattern. For each
section, 150 to 200 individual images were taken per
channel. Individual images were tiled together using Image-
Pro. Confocal images were taken with a Leica SP5 microscope
using the following settings: Fluorescein was excited with an
argon laser at 458 nm, emission 500 to 560 nm; Cy3 was
excited with an HeNe laser at 545 nm, emission 550 to
650 nm; Alexa647 was excited with an HeNe laser at
633 nm, emission collected 650 to 720 nm. Images were
analyzed using LAS AF Lite software (Leica).
Human Choroid Plexus Epithelial Cell and Human
Brain Microvascular Endothelial Cell Culture; In
Vitro HapoA-I Uptake, Binding, Transport, and
Degradation Assays
Primary human choroid plexus epithelial cells (hCEpiCs) and
human brain microvascular endothelial cells (hBMECs; Scien-
Cell Research Laboratories) were cultivated using either
complete epithelial or endothelial cell medium containing
the provided supplements (ScienCell Research Laboratories)
and used between passages 4 to 8. For uptake and
colocalization assays, hCEpiCs and hBMECs were seeded at
59104 cells per well onto rat-tail collagen-coated cover slips
and grown until conﬂuent. On the assay day, cells were
incubated with 50 lg/mL each of Alexa647–rhapoA-I and
Alexa Fluor 488–labeled hapoA-I in DMEM containing 0.2%
bovine serum albumin and 10 mmol/L HEPES for 1 hour at
37°C. To determine whether hapoA-I colocalizes with the
lysosome, cells were seeded as above and incubated with
200-nm LysoTracker Green DND-26 (Invitrogen) and 50 lg/
mL Alexa647–rhapoA-I for 1 hour at 37°C. Following incuba-
tion, cells were washed twice with PBS, ﬁxed in 3.75%
paraformaldehyde for 30 minutes, and washed with 0.5 mol/
L Tris HCl, pH 8. After 2 additional PBS washes, cells were
mounted in 0.1 mol/L Tris-HCL, pH 9.5, and glycerol (3:7)
containing 50 mg/mL n-propyl gallate as an antifading
reagent containing DAPI (1 ng/mL; Sigma-Aldrich) onto
Superfrost Plus glass slides.20
Radiolabeling, cell binding, and transport assays were
performed as described.21 Brieﬂy, 1 mg of hapoA-I was
incubated with 1 mCi of sodium iodide and 2 iodobeads
(Pierce) for 15 minutes at room temperature. Proteins were
separated from free iodine 125 (125I) using a Sephadex G-25
(Sigma-Aldrich) column followed by an intensive dialysis
against 7.5 mol/L NaCl and 15 mmol/L EDTA to remove free
125I. For cellular binding, hCEpiCs and hBMECs were seeded
at 89104 cells per well in 12-well dishes in growth media and
grown until conﬂuent (2 days). On the assay day, cells were
washed once, incubated on ice cold assay medium (DMEM
with 0.2% lipid-free bovine serum albumin and 10 mmol/L
HEPES) for 30 minutes, and then incubated at 4°C for 1 hour
with 5 lg/mL 125I-labeled hapoA-I alone or competed with
40-fold excess of nonlabeled hapoA-I in assay medium. For
transport assays, hCEpiCs and hBMECs were seeded at 6 to
89104 cells per well onto rat-tail collagen-coated 0.3-cm2,
0.4-lm transwell inserts (353095; Corning) in growth media.
Barrier formation was conﬁrmed by measuring permeability to
4-kDa FITC-dextran (average cellular permeability 3.1 910 6
 3.09107 cm/s hCEpiCs, 1.7 9 106  9.9 9107
cm/s hBMECs). On the assay day, cells were incubated at
37°C for 1 hour with 5 lg/mL 125I-labeled hapoA-I alone or
competed with 40-fold excess of nonlabeled hapoA-I in assay
medium. After 1 hour, cells were washed once with Tris wash
buffer (50 mmol/L Tris–HCl, 0.15 mol/L NaCl, pH 7.4)
containing 2 mg/mL bovine serum albumin, followed by 2
quick washes with Tris wash buffer without bovine serum
albumin. Cells were then lysed in 0.1 mol/L NaOH for
30 minutes at room temperature. Radioactivity in the cell
lysate or basolateral media was measured using a Beckman c-
counter. For binding assays, the concentration of 125I-labeled
hapoA-I per well was normalized to total protein concentration
(ng/mg) and then expressed relative to cells treated with 125I-
labeled hapoA-I alone for each experiment. For transport
assays, raw count-per-minute data were expressed relative to
cells treated with 125I-labeled hapoA-I alone for each exper-
iment.
In addition to LysoTracker colocalization experiments,
potential degradation of hapoA-I by hCEpiCs and hBMECs
was assessed using both radioactivity and denaturing immu-
noblotting. The radioactive degradation assay was performed
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as described previously.21 Brieﬂy, cells were seeded at 89104
cells per well in 12-well dishes and grown until conﬂuent. On
the day of the assay, the cells or control empty wells were
incubated with 5 lg/mL 125I-labeled hapoA-I in the absence
or presence of 40-fold excess of nonlabeled hapoA-I in assay
medium. After incubation for 4 hours at 37°C, the amount of
125I-labeled apoA-I degradation products released into the
medium was measured. The proteins in the incubation
medium were precipitated with trichloroacetic acid. To
distinguish cellular degradation products from free iodine in
solution after trichloroacetic acid precipitation, the superna-
tant was oxidized by hydrogen peroxide and free iodine was
extracted with trichloroethane. The radioactivity in the
aqueous phase containing cellular degradation products was
measured using a Perkin Elmer c-counter. In the denaturing
immunoblotting experiments, hCEpiCs and hBMECs were
seeded in transwell inserts, as detailed above, grown until
conﬂuent, and then incubated for 1 hour at 37°C with
0.5 mg/mL hapoA-I in assay medium. The basolateral media
was collected, concentrated 10-fold using a 3-kDa cutoff
ﬁlter, and subjected to denaturing immunoblotting using 4% to
12% NuPAGE Bis-Tris gradient gels (Invitrogen) and a human-
speciﬁc apoA-I antibody (1:1000; Brookwood Biomedical).
Kinetic Modeling
The half-life of hapoA-I in plasma was determined by ﬁtting
the experimental data to a 2-compartment decay model using
the following equation: P=Aeat+Bebt. For tissue, data were
normalized to initial values except for brain, which peaked at
2 hours, and the ﬁrst-order elimination half-lives were
determined from the slopes of lines ﬁtted to the natural
logarithm of normalized experimental data at different time
points. The ﬁtting of the equation to experimental data was
done using Origin 7.0 (OriginLab).
Statistics
Data were analyzed either by Student unpaired t test for
normally distributed data or Mann–Whitney test for nonpara-
metric data. Normality was assessed using the D’Agostino
Pearson normality test. All analyses were performed by
GraphPad Prism v5.0.
Results
In mice, steady-state endogenous apoA-I levels in CSF, ISF,
and perfused brain tissue are, respectively, 0.018%, 0.0036%,
and 10% to 15% of levels in plasma and liver.
We started by quantifying the steady-state levels of
endogenous murine apoA-I in peripheral versus CNS
compartments in 3- to 4-month-old female C57Bl/6 mice.
Consistent with previous reports, we were unable to detect
apoA-I mRNA in cortical tissue obtained from C57Bl/6 mice or
primary human epithelial and endothelial cell lines derived
from the choroid plexus and brain microvasculature, respec-
tively, indicating that the apoA-I we detect in the CNS is most
likely derived exclusively from the circulation following
expression by the liver and intestine (Figure 1A). Commercially
available highly sensitive ELISAs were used in conjunction with
denaturing immunoblotting to determine the absolute and
relative concentrations of apoA-I protein in the CNS compared
with the periphery (Figure 1B through 1F). By ELISA, apoA-I
measured 3932265 lg/mL in plasma, 0.6640.046 lg/
mL in CSF, and 0.1400.018 lg/mL in hippocampal ISF
microdialysis samples (Figure 1B). Densitometric analysis of
denaturing immunoblots of serially diluted plasma, used to
generate a standard curve, and CSF (Figure 1C) or ISF
(Figure 1D) conﬁrmed that the relative levels of murine
apoA-I in CSF (0.0120.003%) and hippocampal ISF
(0.00160.0003%) are comparable to those determined by
ELISA (0.01810.0016% for CSF and 0.003670.0005% for
hippocampal ISF) (Figure 1E). Because the ELISA signal-to-
noise ratio was too low to provide accurate quantitation in
tissue lysates, the relative proportion of apoA-I in brain tissue
was determined by denaturing immunoblotting. Liver lysates
were similarly diluted and compared with lysates from cortex,
hippocampus, and cerebellum of well-perfused C57Bl/6 and
apoA-I/ mice (Figure 1F). Densitometric analysis shows
that brain levels of murine apoA-I are 10% to 15% of liver
levels across 3 brain regions (Figure 1G).
Elimination of Intravenously Injected RhapoA-I
From the CNS
To study the uptake, turnover, and elimination of plasma-
derived apoA-I in the CNS, mice were injected intravenously
via the tail vein with 60 mg/kg of lipid-free Alexa647–rhapoA-
I, and samples were collected 30 minutes to 24 hours after
injection. Tissues collected from well-perfused mice were
homogenized, and the levels of rhapoA-I were quantiﬁed by
ELISA (Figure 2A through 2E). RhapoA-I measured
1577192 lg/mL in plasma taken 1 minute after injection,
in agreement with the theoretical maximum of 1250 lg/mL,
given the total milligrams of rhapoA-I injected and the
theoretical plasma volume based on body weight (Figure 2A).
Using a 2-compartment decay model, the half-life of plasma
rhapoA-I during the short distribution phase was calculated to
be 0.9 hour, after which turnover slowed with an elimination
half-life of 10.9 hours. Peak rhapoA-I concentrations in liver,
0.0270.005 lg/mg, and kidney, 0.3260.174 lg/mg,
were detected at the earliest assessed time point, after
which they were eliminated by ﬁrst-order decay for the ﬁrst
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Figure 1. Steady-state endogenous apoA-I levels in 3- to 4-month-old female C57Bl/6 mice. A, ApoA-I
mRNA levels were quantiﬁed using qRT-PCR. Murine apoA-I (solid bars) was measured in cortical tissue and
expressed relative to liver samples taken from matched C57Bl/6 mice. Tissue from apoA-I/ mice was
used as a background control. Human apoA-I (diagonal stripes) was measured in primary hCEpiCs and
primary hBMECs and expressed relative to HepG2. Graphs represent meanSEM with n=2 (cell lines), n=3
(cortical tissue), or n=4 (liver tissue) per group. B, ApoA-I was measured in plasma, CSF, and ISF
microdialysis samples taken from C57Bl/6 mice by commercial ELISA. Hippocampal ISF microdialysis
samples were collected at a constant ﬂow rate of 1.0 lL/min. Plasma and CSF samples from apoA-I/
mice were used as background controls. Graphs represent meanSEM with n=6 (ISF) or n=9 (plasma and
CSF) per group. C, Representative denaturing apoA-I immunoblot of plasma (Pl) and CSF from 3 individual
C57Bl/6 and apoA-I/ mice. We subjected 5 µL diluted plasma (1:4000 to 1:32 000) and undiluted CSF
to denaturing gel electrophoresis followed by immunoblotting with a murine speciﬁc apoA-I antibody. D,
Representative denaturing apoA-I immunoblot of plasma and ISF from 5 individual C57Bl/6 mice. We
subjected 20 µL diluted plasma (1:20 000 to 1:120 000) and undiluted ISF to denaturing gel
electrophoresis followed by immunoblotting with a murine speciﬁc apoA-I antibody. E, Relative apoA-I
concentration as determined by ELISA (solid bars) or denaturing immunoblotting followed by densitometry
(striped bars) expressed relative to plasma. Graphs represent meanSEM with n=5 (ISF by immunoblot),
n=6 (ISF by ELISA), n=7 (plasma by immunoblot), n=8 (CSF by immunoblot), or n=9 (plasma and CSF by
ELISA) per group. F, We subjected 25 to 150 lg of liver and 150 lg of cortex, hippocampus and cerebellum
lysates from C57Bl/6 mice to denaturing gel electrophoresis followed by immunoblotting against apoA-I.
Tissue samples from apoA-I/ mice were used as a negative control. G, Relative tissue apoA-I levels were
determined by densitometry and expressed relative to liver apoA-I. Graphs represent meanSEM with n=4.
Apo indicates apolipoprotein; Cb, cerebellum; CSF, cerebrospinal ﬂuid; Cx, cortex; hBMEC, human brain
microvascular endothelial cells; hCEpiC, human choroid plexus epithelial cells; HepG2, immortalized
hepatocytes; Hp, hippocampus; ISF, interstitial ﬂuid; Lv, liver; qRT-PCR, quantitative reverse transcriptase
polymerase chain reaction; WT, wild-type.
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2 hours with half-lives of 14.3 hours (R2=0.998) in liver and
2.1 hours (R2=0.939) in kidney (Figure 2B and 2C). In
contrast, rhapoA-I concentrations in total brain lysates
reached maximum levels 2 hours after injection, at
2.960.56 ng/mg, after which it was also eliminated by
ﬁrst-order decay with a half-life of 10.3 hours between 2 and
24 hours (R2=0.976) (Figure 2D). In the CSF, maximal
rhapoA-I levels were detected 30 minutes after injection, at
0.0880.004 lg/mL, after which they subtly declined to
0.0680.024 lg/mL 6 hours after injection and were unde-
tectable 24 hours after injection (Figure 2E). These concen-
trations equate to 0.008% to 0.012% of plasma levels, similar
to the 0.0181% ratio determined for steady-state endogenous
murine apoA-I (Figure 1). By 24 hours after injection, the
levels of rhapoA-I in plasma, liver, kidney, and brain were
9.4%, 14.1%, 1.9%, and 11.9% of their maximum concentra-
tions, respectively.
We also determined the regional distribution of Alexa647–
rhapoA-I within the CNS in our elimination experiments using
semiquantitative imaging. Maestro ﬂuorescent imaging of
intact half brains showed detectable ventricular ﬂuorescence
within 30 minutes of injection, peak intensity between 2 and
6 hours after injection, and a decline of signal intensity
thereafter, in accordance with our ELISA observations for
brain tissue (Figure 3).
Intravenously Injected RhapoA-I Shows
Dose-Dependent Uptake in Brain
To test for dose-dependent uptake of plasma-derived apoA-I
uptake into the CNS, mice were injected intravenously via the
tail vein with 7.5 to 120 mg/kg Alexa647–rhapoA-I, and
tissue samples were collected 2 hours after injection, when
the brain shows maximal rhapoA-I uptake. Levels of rhapoA-I
A B C D E
Figure 2. Alexa647-rhapoA-I accumulates in the CNS for up to 2 hours prior to elimination. Mice were injected with saline or 60 mg/kg of
Alexa647-rhapoA-I. After 0.5, 1, 2, 3, 6, or 24 hours, mice were perfused, and the concentrations of rhapoA-I in (A) plasma, (B) liver, (C) kidney,
(D) brain, and (E) CSF were determined by commercial ELISA and normalized to total protein concentration in tissues. Graphs represent
meanSEM, with n=2 (3 hours), n=3 (0.5 hour), n=4 (1 hour, 2 hours), or n=5 (6 and 24 hours) for tissue and n=3 to 5 for CSF samples.
Alexa647 indicates Alexa Fluor 647 labeled; CNS, central nervous system; CSF, cerebrospinal ﬂuid; rhapoA-I, recombinant human apolipoprotein
A-I.
A B
Figure 3. Alexa647-rhapoA-I is retained in cerebral ventricles up to 6 hours after a single injection. A,
Representative Maestro ﬂuorescent images of perfused intact half brains 0.5 to 24 hours following
intravenous injection with saline or 60 mg/kg of Alexa647-rhapoA-I. B, Quantiﬁcation of ﬂuorescence in
photon9106/cm2 per second was measured for each mouse and plotted following subtraction of
background signal found in controls. Graphs represent meanSEM, with n=2 (0.5 hour), n=4 (2 hours), and
n=5 (6 and 24 hours). Alexa647 indicates Alexa Fluor 647 labeled; rhapoA-I, recombinant human
apolipoprotein A-I.
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in plasma and lysates from liver, kidney, and brain tissue of
well-perfused mice were quantiﬁed by ELISA (Figure 4). As
expected, plasma levels of rhapoA-I increased with increasing
injected dose (Figure 4A). In liver, the concentration of
rhapoA-I rapidly increased between 7.5 and 60 mg/kg and
began to plateau at 120 mg/kg (Figure 4B). In kidney,
rhapoA-I levels again showed a direct relationship with
injected dose, reﬂecting the role of the kidney in clearing
lipid-poor apoA-I (Figure 4C). Because only a small proportion
of injected rhapoA-I reaches the brain, the dose-dependency
curve is more variable than for other tissues. Nevertheless, we
observed that brain levels of rhapoA-I reached roughly 1.5 to
2.5 ng/mg for animals injected at 15, 30, and 60 mg/kg,
whereas injection at 120 mg/kg led to a further increase to
5.951.08 ng/mg (Figure 4D). Peak concentrations of
rhapoA-I after injection with 120 mg/kg reached 1260
72 lg/mL in plasma, 0.0830.009 lg/mg in liver, and
0.1420.028 lg/mg in kidney (Figure 2A through 2C).
Importantly, rhapoA-I levels in brain are 5% to 15% of those
found in liver, comparable to the relative steady-state levels
for endogenous murine apoA-I (Figure 1).
Intravenously Injected Alexa647–RhapoA-I
Rapidly Localizes to Cerebral Ventricles and the
Choroid Plexus
We next determined the regional distribution of Alexa647–
rhapoA-I within the CNS using semiquantitative imaging.
Maestro ﬂuorescent imaging of intact half brains
demonstrates dose-dependent accumulation of ﬂuorescence
within the cerebral ventricles between 7.5 and 120 mg/kg
(Figure 5A and 5B). To visualize the regional distribution of
Alexa647–rhapoA-I in entire brain sections at high magniﬁca-
tion, 40-lm sagittal sections were generated and imaged at
9100 magniﬁcation using ﬂuorescent microscopy. Using
specialized computer software, 150 to 200 images were
taken per section and stitched together to yield a high-
resolution image of the complete sagittal section (Figure 6).
This technique conﬁrmed that after injection into the blood-
stream, Alexa647–rhapoA-I is located almost exclusively in
the choroid plexus of the lateral and fourth ventricles and is
virtually undetectable in the brain vasculature (Figure 6). The
pattern of Alexa647–rhapoA-I distribution appeared the same
in mice injected at all doses of hapoA-I used (data not shown).
As with Maestro imaging, we also observed a dose-dependent
increase of Alexa647–rhapoA-I within the choroid plexus
when sagittal sections were examined (Figure 7A and 7B).
Endogenous IgG is also visible within the choroid plexus but
does not show the dose-dependent accumulation observed
for hapoA-I (Figure 7C and 7D). Furthermore, because we
observed no IgG extravasation around the cerebrovasculature
or choroid vessels in treated mice (data not shown), our
results indicate that neither the BCSFB nor the BBB is
compromised, even at the highest dose of Alexa647–rhapoA-I
used.
We then performed confocal microscopy to determine the
precise localization of Alexa647–rhapoA-I compared with
plasma IgG in the choroid plexus. In both saline and
Alexa647–rhapoA-I–injected mice, IgG staining is most
intense within the vasculature, with only faint extravascular
staining visible (Figure 8A and 8B). In contrast, the Alexa Fluor
647 signal is intensely localized within the epithelial cells of
the choroid plexus of mice injected with Alexa647–rhapoA-I
(Figure 8B and 8C), suggesting its cellular uptake.
We also conﬁrmed barrier integrity by coinjecting Evans
blue dye into a subgroup of animals 30 minutes prior to
sacriﬁce. As expected, plasma, liver, and kidney samples stain
deep blue, indicating the uptake of Evans blue dye bound to
A B C D
Figure 4. Dose-dependent increase of Alexa647-rhapoA-I in plasma, liver, kidney, and brain. Mice were injected with 7.5 to 120 mg/kg
Alexa647-rhapoA-I. At 2 hours after injection, tissue lysates were prepared from perfused mice. RhapoA-I concentrations in (A) plasma and in
perfused (B) liver, (C) kidney, and (D) brain were determined by ELISA and normalized to total protein concentration for tissues. Graphs
represent meanSEM, with n=2 (30 mg/kg), n=4 (7.5 mg/kg), n=5 (15 mg/kg), and n=6 (60 and 120 mg/kg). Alexa647 indicates Alexa Fluor
647 labeled; rhapoA-I, recombinant human apolipoprotein A-I.
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albumin (Figure 9A), yet the brain remains pale, indicating
that hapoA-I treatment did not compromise barrier integrity
(Figure 9B). Evans blue dye is visible within the lateral
ventricle when half brains are visualized using ﬂuorescent
imaging, reﬂecting the known transport of 0.1% to 0.3% of
plasma albumin into the CSF under normal circumstances
(Figure 9C).22 Taken together, these observations suggest
that circulating hapoA-I may gain access to CSF via transport
across the choroid plexus.
In Vitro, Cultured Primary Human Choroid Plexus
Epithelial and Primary Human Brain
Microvascular Endothelial Cells Show Similar
ApoA-I Binding, Internalization, and Transport
Activities
Intravenously injected hapoA-I clearly gains access to the
choroid plexus, CSF, and brain tissue in mice, but whether this
may occur in humans is not known. Consequently, we
performed in vitro experiments using monotypic cultures of
primary hCEpiCs and primary hBMECs. Although we did not
detect noticeable ﬂuorescence from Alexa647–rhapoA-I
within or around the brain microvasculature in treated mice,
we cannot rule out that a fraction of hapoA-I may also be
transported across the endothelium of the BBB, as has been
previously reported in porcine monotypic in vitro cell culture
systems.23 HapoA-I internalization, binding, and transport by
hCEpiCs and hBMECs were characterized using hapoA-I
labeled with an Alexa ﬂuorophore or 125I (Figures 10 and 11).
Using ﬂuorescent microscopy, internalized Alexa-labeled
hapoA-I was located in perinuclear vesicles, with strong
colocalization occurring between recombinant Alexa647–
rhapoA-I (red) and serum-derived Alexa Fluor 488-labeled
hapoA-I (green), suggesting that epithelial and endothelial
uptake is not altered by the point mutations present in the
recombinant Alexa647–rhapoA-I protein (Figure 10A). For
binding and transport assays, cells were incubated with 125I-
labeled hapoA-I alone or in the presence of 40-fold excess of
unlabeled hapoA-I as a speciﬁc competitor. Speciﬁc binding
and transport were determined by subtracting the counts
obtained in the presence of excess cold hapoA-I from the total
counts and expressed relative to control hCEpiCs or hBMECs
(Figure 10B and 10C). Binding of 125I-labeled hapoA-I, mea-
sured at 4°C to prevent internalization, was signiﬁcantly
decreased from 10026.9% to 53.114.4% in hCEpiCs
(P<0.0001) and from 10020.1% to 59.513.7% in hBMECs
(P<0.0001) when competed with excess cold hapoA-I
(Figure 10B). We then measured the ability of cells grown
on transwell inserts to transport 125I-labeled hapoA-I from the
apical to basolateral compartment. Transport of 125I-labeled
hapoA-I was decreased signiﬁcantly in hCEpiCs, from
1006.4% to 67.414.7% (P<0.0001), and from 1008.3%
to 72.213.0% (P<0.0001) in hBMECs when competed with
excess cold hapoA-I (Figure 10C). Importantly, competition
with of 125I-labeled hapoA-I with bovine serum albumin did not
alter the binding or transport of 125I-labeled hapoA-I in either
cell type (data not shown), suggesting that both hCEpiCs and
hBMECs can bind, internalize, and transport hapoA-I via
speciﬁc cellular mechanisms.
Last, we sought to determine whether hapoA-I is degraded
by either hCEpiCs or hBMECs (Figure 11). Using ﬂuorescent
microscopy, we observed no signiﬁcant colocalization of
Alexa647–rhapoA-I with a lysosomal marker in either cell type
(Figure 11A). Fragments of hapoA-I, indicating degradation,
were not detected in conditioned media using highly sensitive
trichloroacetic acid precipitation assays or via denaturing
A B
Figure 5. Dose-dependent accumulation of Alexa Fluor 647-labeled rhapoA-I in cerebral ventricles and
the choroid plexus: Mice were injected intravenously with saline or 7.5 to 120 mg/kg of Alexa Fluor 647-
labeled rhapoA-I. At 2 hours after injection, mice were perfused and half brains were ﬁxed. A, Maestro
ﬂuorescent imaging of the intact ﬁxed half brain. B, Quantiﬁcation of ﬂuorescence using Maestro imaging.
Raw signal was measured in photon9106/cm2 per second for each mouse and subsequently converted to
fold difference with the saline injected control set to 1, allowing for combination of data from 2 independent
experiments. Graphs represent meanSEM, with n=2 (30 mg/kg), n=3 (7.5 mg/kg), n=5 (15, 60, and
120 mg/kg), or n=6 (saline control). Alexa647 indicates Alexa Fluor 647 labeled; rhapoA-I, recombinant
human apolipoprotein A-I.
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immunoblotting (Figure 11B and 11C). Taken together, these
results support the hypothesis that internalized hapoA-I is not
routed for degradation following internalization at the apical
side of primary hCEpiCs or hBMECs but may be transported
through the polarized cell for eventual secretion from the
basolateral side.
Discussion
Potential roles for apoA-I-containing HDL in cerebrovascular
health and AD pathogenesis are emerging from both epide-
miological and animal studies.5 The levels and, more impor-
tant, the cholesterol efﬂux capacity and vasoprotective
properties of HDL decrease during aging24 and decrease
even more so with comorbid conditions such as cardiovas-
cular disease and type 2 diabetes mellitus8,9 that are
associated with increased AD risk.6,7 Higher levels of
circulating plasma apoA-I at midlife25 and HDL-C later in
life26 are associated with signiﬁcantly reduced AD risk, even
after adjusting for APOE genotype and other vascular risk
factors. Plasma apoA-I is reduced by 20% to 30% in patients
with mild AD compared with age-matched nondemented
controls.27–30 In patients with AD, plasma levels of apoA-I are
positively correlated with measures of cognitive function,
such as the Cognitive Abilities Screening Instrument and the
Mini-Mental State Examination,29,30 and negatively correlated
with measures of brain atrophy.31 Intriguingly, low plasma
HDL-C was recently associated with and predicted higher
amyloid binding, as measured using Pittsburgh compound B
positron emission tomography of cognitively normal subjects
Figure 6. Intravenously injected Alexa647-rhapoA-I strongly localizes to the choroid plexus. Represen-
tative tiled ﬂuorescent images of 40-lm sagittal sections generated from mice injected intravenously with
saline (top panel) or 7.5 mg/kg Alexa647-rhapoA-I (bottom panel) taken using the Cy5 ﬁlter to detect the
Alexa Fluor 647 tag. For each section, 150 to 200 individual ﬂuorescent images were taken in a
sequential fashion and stitched together using automated software (Olympus). Alexa647-rhapoA-I
indicates Alexa Fluor 647-labeled recombinant human apolipoprotein.
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and elderly subjects with mild cognitive impairment, indepen-
dent of APOE4.32 Within the CNS, alterations to apoA-I are
less clear, potentially due to the small sample sizes of existing
studies: ApoA-I levels in brain tissue and CSF33–35 of AD
subjects have been reported to be decreased, although 2
other studies36,37 found no difference in CNS apoA-I levels.
Because apoA-I is found in the CSF of many species, despite
being synthesized only in liver and intestine,5 this study was
designed to explore the mechanisms by which circulating
apoA-I accesses the CNS. Our ﬁndings suggest that injected
hapoA-I gains access to the CNS via preferential uptake by the
epithelial cells of the choroid plexus via a speciﬁc cellular
mechanism that remains to be deﬁned. Choroid epithelial
cells may retain a portion of internalized rhapoA-I and secrete
internalized rhapoA-I into the CSF, where it can be exchanged
into the ISF. Although we did not observe localization of
injected rhapoA-I in the cerebral vasculature in vivo, in vitro
monotypic cultures of human choroidal epithelial and vascular
endothelial cells both demonstrated the ability to bind,
internalize, and transport hapoA-I in a speciﬁc manner. As
such, we cannot rule out the possibility that a portion of
hapoA-I is also transported across the BBB. Given that the
surface area of the BBB for transport of molecules is 5000
times larger than that of the choroid plexus epithelium, even a
small contribution of apoA-I transport across BBB endothelial
cells may have a large effect in vivo. Further experiments will
A B
C D
Figure 7. Dose-dependent accumulation of Alexa647-rhapoA-I but not plasma IgG in the choroid plexus of mice injected with saline or
increasing doses of Alexa647-rhapoA-I. Mice were injected intravenously with saline or 7.5 to 120 mg/kg Alexa647-rhapoA-I in saline. Sagittal
sections were generated from ﬁxed, perfused half brains taken 2 hours after injection for microscopic analysis. A, Representative 9100
ﬂuorescent images showing accumulation of Alexa Fluor 647 ﬂuorescence in the choroid plexus of the lateral ventricle. Scale bar represents
500 lm. B, Graphical representation of percent area covered by Alexa647-rhapoA-I in the choroid plexus quantiﬁed by Image-Pro software.
Graph represent meanSEM for n=2 (7.7, 30, 60, 120 mg/kg) or n=3 (15 mg/kg) mice. C, Representative 9100 ﬂuorescent images showing
immunohistochemical detection of IgG in the choroid plexus using a Cy3-conjugated antibody against murine IgG. Scale bar represents 500 lm.
D, Graphical representation of percentage of area covered by IgG quantiﬁed using Image-Pro software. Graph represents meanSEM of n=2 (30
and 60 mg/kg), n=3 (7.5 and 120 mg/kg) or n=4 (15 mg/kg) mice. Alexa647 indicates Alexa Fluor 647 labeled; CP, choroid plexus; rhapoA-I,
recombinant human apolipoprotein.
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be required to determine whether the differences between our
in vivo and in vitro observations are due to species differences
or to the use of monotypic cultures with behavior in culture
that may not be fully representative of internalization and
transport activities of corresponding cell types in vivo.
With a few exceptions, transport into and out of the CNS is
tightly regulated by a set of barriers, namely, the BCSFB,
between the blood and the CSF, and the BBB, between the
blood and brain tissue. Previous studies examining apoA-I
entry into the CNS have focused primarily on endothelial
A B C
Figure 8. Alexa647-rhapoA-I is internalized by choroid plexus epithelial cells, whereas plasma IgG is
retained within the vascular endothelium supplying the choroid plexus. Representative confocal images of
the choroid plexus taken at 9400 magniﬁcation from mice injected with (A) saline or (B) 60 mg/kg
Alexa647-rhapoA-I at 30 minutes after injection. Sagittal sections were costained with lectin (green) to
visualize endothelial and epithelial cells and Cy3-conjugated IgG (blue) as a plasma marker. The Alexa Fluor
647 signal from rhapoA-I is shown in red. C, Enlarged view of (B) shown at full size for a selected region of
each channel as depicted by the white box outline. Scale bar represents 25 lm. Alexa647 indicates Alexa
Fluor 647 labeled; rhapoA-I, recombinant human apolipoprotein.
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transport. Protamine-oligonucleotide nanoparticles, or proti-
cles, coated with apoA-I exhibited increased uptake and
transcytosis across in vitro primary porcine brain capillary
endothelial cells cultured on transwells.23 Increased delivery
of apoA-I–coated proticles to astrocytes cocultured on the
basolateral side of the transwell insert was also observed,
although 93% to 94% of these proticles were degraded.23
Incubation with an anti-SR-BI antibody blocked
apoA-I–induced increase in proticle transport,23 consistent
with SR-BI mediating the uptake of HDL-associated choles-
terol esters38 and phosphatidylcholine39 in porcine brain
capillary endothelial cells in vitro. That we observed virtually
no degradation of hapoA-I in our transport assays suggests
that proticle transport may be fundamentally different than
transport of free hapoA-I or that cultured human cells may
behave differently than porcine cells with respect to transport.
In mice, Zensi et al observed that human serum albumin
nanoparticles covalently linked to apoE40 or apoA-I41 were
detected within the endothelial cells of the BBB and brain
parenchyma by transmission electron microscopy 15 to
30 minutes following intravenous injection. Taken together,
these results suggest that apoA-I may facilitate uptake of
exogenous particles across the BBB. However, the behavior of
free apoA-I or apoA-I within HDL, as it is normally found, may
differ from apoA-I when it is coupled to cargo destined for
CNS uptake.
The novelty of our study lies in the fact that we used both
in vitro and in vivo methods to examine the question of apoA-I
transport into the CNS. Although the apoA-I we injected was
initially lipid-free, apoA-I is known to quickly acquire lipids and
associate with endogenous HDL once in circulation.42 In vivo,
transport across the murine BCSFB is clearly observed,
whereas—to our surprise—we could ﬁnd no evidence of
rhapoA-I within the cerebral vasculature of treated mice,
although we note that our methods may not have sufﬁcient
sensitivity to detect rhapoA-I within the cerebrovasculature. In
vitro, primary hCEpiCs and hBMECs are able to bind,
internalize, and transport intact hapoA-I with virtually identical
efﬁciency (Figures 10 and 11). Consequently, the largest
issue raised by our results is to explain the difference
between the in vivo and in vitro observations. Potential
species differences between murine and human cells is one
clear possibility, and others include factors related to the
conditions used for monotypic cell culture. The primary
human cells used for our in vitro experiments were derived
from separate donors, and the speciﬁc passage number could
also inﬂuence protein expression and activity. Most likely is
that monotypic cultures do not replicate the in vivo micro-
environment in which these cell types normally reside. Further
experiments will be required to improve the culture conditions
so they are more representative of in vivo conditions for the
eventual identiﬁcation of the transport mechanisms involved.
Last, specialized areas of the brain called the circumventric-
ular organs, located in the walls of the third and fourth
ventricle, are similar to the BCSFB in that they contain highly
permeable fenestrated endothelial cells.43 Because they lack
A B
C
Figure 9. Abundant Evans blue dye uptake in the liver, kidney, and plasma but not brain in rhapoA-I
treated mice. At 30 minutes prior to sacriﬁce, mice were coinjected with a 2% solution of Evans blue dye
(EB) in addition to a previous injection of either saline or Alexa647-rhapoA-I. Following perfusion, tissue
samples were removed and photographed to compare the relative uptake of Evans blue dye, which binds to
circulating albumin. A, Scanned image of kidney, liver, and plasma showing abundant dark blue staining in
those mice injected with Evans blue dye, regardless of Alexa647-rhapoA-I. B, Scanned image of brains
taken from corresponding mice. C, Fluorescent imaging of the same half brains depicted above revealing
minimal and expected uptake of Evans blue dye–labeled plasma albumin into the ventricular system.
Alexa647 indicates Alexa Fluor 647 labeled; rhapoA-I, recombinant human apolipoprotein A-I.
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a formal BBB, circumventricular organs allow for rapid
exchange and communication between the circulation and
the regional neurons that regulate the release of neurohor-
mones and uptake of circulating metabolites.43 Recent
research has demonstrated the presence of a restrictive
tight-junction–expressing barrier between the circumventric-
ular organs and the CSF formed by tanycyte-like ependymal
cells that form the ventricular wall, similar to the epithelial
A
B C
Figure 10. In vitro uptake, binding, cell association, and transport of hapoA-I by primary monotypic
hCEpiCs and hBMECs. A, Representative ﬂuorescent images taken at 9400 magniﬁcation of hCEpiCs (top
row) and hBMECs (bottom row) coincubated with 50 lg/mL each of Alexa488-hapoA-I (green) and
Alexa647-rhapoA-I (red) for 1 hour, depicting DAPI-stained nuclei (blue). Scale bar represents 25 lm. B,
Speciﬁc binding (4°C) and (C) transport (37°C) of hapoA-I by hCEpiCs and hBMECs was measured by
incubating 5 lg/mL iodine 125–labeled hapoA-I in the absence or presence of a 40-fold excess unlabeled
hapoA-I for 1 hour at the indicated temperature. Values were calculated as counts per minute per well for
transport and counts per minute per well per milligram of total protein for binding. Speciﬁc binding and
transport were determined by subtracting the value obtained in the presence of excess unlabeled hapoA-I
from the total for each well. Values were then expressed relative to control hCEpiC and hBMEC wells to pool
experiments. Graphs represent meanSD from 4 independent experiments and a total of 12 wells per
condition. Statistics were calculated using an unpaired Student t test for normally distributed data (binding
hBMECs, transport hCEpiCs and hBMECs), or a Mann–Whitney test (binding hCEpiCs). Alexa488 indicates
Alexa Fluor 488 labeled; Alexa647, Alexa Fluor 647 labeled; hBMEC indicates human brain microvascular
endothelial cell; hCEpiC, human choroid plexus epithelial cell; hapoA-I, human apolipoprotein A-I; 125I, iodine
125 labeled; rhapoA-I, recombinant human apolipoprotein.
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cells of the choroid plexus.44 Notably, we did not observe
marked uptake of hapoA-I in circumventricular organs in
whole sagittal sections of treated mice.
Endothelial and epithelial cells may have distinct mecha-
nisms by which apoA-I transport is regulated. In aortic
endothelial cells, ABCA1 and the ectopic b-ATPase mediate
cell-surface internalization and transport of lipid-free apoA-
I.45,46 In the kidney, apoA-I is ﬁltered by epithelial cells in the
renal proximal tubule by a combination of the multiligand
endocytic receptors cubilin, megalin, and amnionless.47
Endocytosis of cubilin complexed to apoA-I is triggered by
binding to megalin, also known as low-density lipoprotein
receptor related protein 2 (LRP2), which delivers cubilin and
associated ligands to the lysosome for degradation.47 Megalin
A
B C
Figure 11. Internalized and transported hapoA-I is not degraded by primary hCEpiCs and hBMECs in
vitro. A, Representative ﬂuorescent images taken at 9400 magniﬁcation of hCEpiCs (top row) and hBMECs
(bottom row) coincubated with 200 nmol/L LysoTracker and 100 lg/mL of Alexa Fluor 647-labeled
rhapoA-I (red) for 1 hour, depicting DAPI-stained nuclei (blue). Scale bar represents 25 lm. B, hCEpiCs
(solid) and hBMECs (striped) were seeded in ﬂat-bottom tissue culture plates and incubated with 5 lg/mL
125I-hapoA-I in the absence or presence of a 40-fold excess unlabeled hapoA-I for 4 hours at 37°C. Empty
wells (checkered) were used as a control. After incubation, the amount of 125I-hapoA-I degradation products
released into the medium was measured. The proteins in the incubation medium were precipitated with
TCA. To distinguish the cellular degradation products from the free iodine in solution after TCA precipitation,
the supernatant was oxidized by hydrogen peroxide and the free iodine extracted with chloroform. The
degradation products in the aqueous phase were subsequently measured. Data is expressed such that the
control empty well is zero. Graphs represent meanSD, with n=3 (hBMEC), n=5 (empty control), or n=7
(hCEpiC) wells per condition from 1 to 2 independent experiments. C, hCEpiCs and hBMECs were seeded in
a transwell insert and grown until a conﬂuent monolayer formed. Cells were incubated with control serum-
free media or 0.5 mg/mL hapoA-I for 1 hour. Empty inserts (far right) were used as a control. After
incubation, the basolateral media was collected and concentrated using a 3-kDa cutoff ﬁlter and subjected
to denaturing immunoblotting with a human-speciﬁc apoA-I antibody. Puriﬁed apoA-I, unconcentrated
(0.5 mg/mL) and concentrated stocks (far left), were run as comparative input controls. C indicates
control; hBMEC, human brain microvascular endothelial cell; hCEpiC, human choroid plexus epithelial cell;
hapoA-I, human apolipoprotein A-I; 125I, iodine 125 labeled; rhapoA-I, recombinant human apolipoprotein;
TCA, trichloroacetic acid.
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is expressed at the apical membrane in the choroid plexus of
multiple species,22 whereas cubilin has been found in the
choroid plexus of the developing rat up to embryonic day
15,48 although its expression patterns within the adult CNS
are unknown. Although megalin and cubilin function in kidney
epithelium as canonical endocytic/catabolic receptors,47
megalin at the choroid plexus may participate in receptor-
mediated transcytosis of a variety of ligands including insulin-
like growth factor,49 leptin,50 and apoJ.51 Furthermore,
cerebrovascular endothelial cells express tight and adherens
junction proteins to form the BBB, whereas endothelial cells in
the capillaries that supply the choroid plexus are fenestrated,
a common feature of nonsinusoidal fenestrated microvascu-
lature found in other tissues such as the proximal tubules of
the kidney, pancreas, and adrenal cortex.22 Barrier properties
are derived from the choroidal epithelium, which, in addition
to actively producing CSF, expresses apical belt-like tight
junctions to form the BCSFB. The BCSFB expresses a
multitude of speciﬁc transporters and receptors that govern
the entry and exit of many compounds into and out of the
CSF.22 Whether megalin, cubilin, or other transporters may
participate in apoA-I transcytosis across the BCSFB is not yet
known. Further delineating the speciﬁc transport mechanisms
and potential receptor involvement will be a critical next step.
There are several caveats for our study. First, the majority
of in vivo experiments used rhapoA-I containing C-terminal
cysteine mutations to facilitate Alexa labeling; however, we
observed strong colocalization between recombinant and
serum-derived hapoA-I in hCEpiCs and hBMECs (Figure 10)
and a similar peak brain concentration (2 to 3 ng/mg)
following intravenous injection of 60 mg/kg serum-derived
hapoA-I (data not shown). These observations suggest that
CNS transport is similar between these 2 hapoA-I prepara-
tions. A second caveat is the measurement of apoA-I, both
endogenous and exogenous, in whole-brain tissue lysates,
which retain both choroid plexus and vascular structures.
Third, despite perfusion of at least 70 mL of saline into
experimental animals, it is possible that a minor proportion of
circulating hapoA-I may remain in the vessel lumen or bound
to vascular endothelial cells, thus overestimating the actual
brain hapoA-I concentration. Further experiments will be
needed to determine whether the apoA-I levels measured in
whole-brain tissue reﬂect hapoA-I that has actually crossed
either the BBB or BCSFB.
One of the aims of this study was to establish the steady-
state levels of murine apoA-I in the CNS compared with
peripheral tissues in young healthy C57Bl/6 mice. The plasma
level of apoA-I in C57Bl/6 mice has been estimated to be
1.10.1 mg/mL based on protein mass quantitation follow-
ing single radial immunodiffusion.52 Comparatively, by ELISA,
we report murine apoA-I to be 2.5 to 3.5 times this value, at
3.80.2 mg/mL. This discrepancy may be explained in part
by the difference in techniques and the greater sensitivity of
ELISA. ApoA-I uptake into the CSF may also be inﬂuenced by
species, age, and barrier integrity status in addition to steady-
state plasma levels. The concentration and ratio of CSF
apoA-I, for example, varies greatly between species: 0.07
0.055 lg/mL (0.01% of plasma) in rats,53 1.30.18 lg/mL
(0.1% of plasma) in macaques,54 3.70.8 lg/mL (0.26% of
plasma) in humans,55 and 8.01.5 lg/mL (0.5% of plasma) in
dogs.56 HapoA-I in the CSF of 12-month-old APP/PS1 mice
crossed to hapoA-I transgenic mice, in which plasma hapoA-I
measures 2.430.96 mg/mL,52 reaches 31 lg/mL, repre-
senting 0.12% of plasma levels,11 or nearly 10-fold the CSF
levels measured in this study; however, these 12-month-old
transgenic AD mice may also have a compromised BBB and/
or BCSFB compared with the 3- to 5-month-old C57Bl/6 mice
used in this study. To our knowledge, apoA-I levels in ISF have
not been measured before. In a recent study, the concentra-
tion of apoE in hippocampal ISF microdialysis samples from
young C57Bl/6 mice, also collected at a ﬂow rate of 1.0 lL/
min, was reported as 0.01010.0018 lg/mL, whereas total
CSF apoE measured 6.0240.152 lg/mL.18 The reported
value of apoA-I in hippocampal ISF microdialysis samples
measured in this study, 0.1400.018 lg/mL, is signiﬁcantly
higher than that reported for apoE, as is the ratio of ISF:CSF
(apoA-I [21%] or apoE [0.17%]). Ulrich et al made the
important observation that the concentration of ISF apoE
was inversely related to the ﬂow rate at which it was
collected; by using a range of ﬂow rates for collection, they
determined that the total amount of exchangeable apoE in ISF
was 0.11120.0144 lg/mL, 10-fold higher than the mean
concentration measured at 1.0 lL/min.18 Whether apoA-I
behaves in a similar fashion or how the interchange of apoA-I
among plasma, CSF, and ISF occurs remains unknown and
may provide further insight into the differences observed.
Like the cerebrovasculature, the choroid plexus develops
structural and functional damage in AD.57 In aging and even
more so in AD, epithelial cell atrophy contributes to a ≥50%
decrease in CSF production, which, in conjunction with
increased ventricular volume, results in lower ﬂow and
turnover of CSF.57 Concomitantly, the concentration of
potentially toxic peptides and metabolites increases, and
the ventricular sink action that draws catabolites from the
ISF into the CSF via a concentration gradient is markedly
decreased.57 Because LRP1-mediated clearance of Ab
across the BBB is compromised in AD,4 the brain may
depend more heavily on reabsorption of ISF Ab by CSF for
transport across the BCSFB.57 Together, multiple
mechanisms may lead to increased Ab deposition in the
choroid plexus, conﬁrmed histologically at post mortem in
patients with AD and in APP/PS1 transgenic AD mice.58,59
Ab deposition is associated with a reduction in
mitochondrial activity, increased generation of reactive
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oxygen species, and expression of caspases 3 and 9,
ultimately leading to increased apoptosis.58,59 Interestingly,
apoA-II exhibited increased oxidative damage in the choroid
plexus of patients with AD, further suggesting that HDL
metabolism at the choroid plexus may be impaired in
advanced AD.58
Both HDL levels and cholesterol efﬂux capacity decline with
age.24 It is not known whether the onset of age-related
dysfunction in either cerebrovascular endothelial cells or
choroid epithelial cells correlate with age-related reductions in
HDL or apoA-I levels. Although HDL and apoA-I have demon-
strated beneﬁcial functions in promoting endothelial cell
health,5 it is not known whether these effects may extend to
cerebrovascular endothelial cells or choroid epithelial cells.
The in vivo and in vitro data shown in this paper support the
conclusion that circulating hapoA-I can be transported through
choroid epithelial cells into the CNS. That cellular binding and
transport can be competed by an excess of unlabeled hapoA-I
suggests that speciﬁc transport pathways exist, and future
studies will determine whether these pathways are similar to
those that regulate transport of apoA-I through endothelial
cells in the periphery. HDL may represent a key interface
between peripheral metabolism and CNS health.
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